Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/31841| Title: | Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study. | Austin Authors: | Shah, Manish A;Yoshino, Takayuki;Tebbutt, Niall C ;Grothey, Axel;Tabernero, Josep;Xu, Rui-Hua;Cervantes, Andres;Oh, Sang Cheul;Yamaguchi, Kensei;Fakih, Marwan;Falcone, Alfredo;Wu, Christina;Chiu, Vi K;Tomasek, Jiri;Bendell, Johanna;Fontaine, Marilyn;Hitron, Matthew;Xu, Bo;Taieb, Julien;Van Cutsem, Eric | Affiliation: | University of Melbourne, Melbourne, Australia. Weill Cornell Medicine, New York, NY; New York-Presbyterian Hospital, New York, NY. Medical Oncology National Cancer Center Hospital East (NCCE), Kashiwa, Japan. West Cancer Center and Research Institute, Germantown, TN. Vall d'Hebron Hospital, Campus and Institute of Oncology (VHIO), IOB-Quiron, UVic- UCC, Barcelona, Spain. Sun Yat-sen University Cancer Center, Guangzhou, China. Incliva Biomedical Research Institute, Valencia, Spain; University of Valencia, Valencia, Spain. Korea University College of Medicine, Seoul, South Korea. Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan. City of Hope Comprehensive Cancer Center, Duarte, CA. University of Pisa, Pisa, Italy; Department of Translational Research, University of Pisa, Pisa, Italy. Winship Cancer Institute, Emory University, Atlanta, GA. The Angeles Clinic & Research Institute, a Cedars-Sinai affiliate, Los Angeles, CA. Masaryk Memorial Cancer Institute, Brno, Czech Republic. Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN. Sumitomo Dainippon Pharma Oncology, Inc., Cambridge, MA. Hôpital Europeen Georges Pompidou, APHP, Paris, France; Université de Paris, Paris, France; CARPEM Cancer Institute, Paris, France. University Hospitals Gasthuisberg, Leuven & KULeuven, Leuven, Belgium. |
Issue Date: | Mar-2023 | Date: | 2022 | Publication information: | Clinical Colorectal Cancer 2023-03; 22(1) | Abstract: | Napabucasin is an investigational, orally administered reactive oxygen species generator bioactivated by intracellular antioxidant NAD(P)H:quinone oxidoreductase 1 that has been evaluated in various solid tumors, including metastatic colorectal cancer (mCRC). Phosphorylated signal transducer and activator of transcription 3 (pSTAT3) is hypothesized to predict response in napabucasin-treated patients with mCRC. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/31841 | DOI: | 10.1016/j.clcc.2022.11.002 | ORCID: | Journal: | Clinical Colorectal Cancer | PubMed URL: | 36503738 | ISSN: | 1938-0674 | Type: | Journal Article | Subjects: | Clinical trial Colon cancer FOLFIRI pSTAT3 phase 3 |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.